Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

'We have a problem with price rises': PSNC CEO answers your questions

From purchase profits to generics price hikes, the Pharmaceutical Services Negotiating Committee's (PSNC) outgoing CEO answered questions from C+D readers this week.

Ms Sharpe – who will be replaced by fraud prevention service CEO Simon Dukes in May – also fielded a reader question on Monday (January 15) about whether she would “stay on in any capacity” to support him.

Watch the video below to see Ms Sharpe’s responses, including her acknowledgement that drug price rises have “been a really big addition to the tremendous financial pressures pharmacists have had to bear over the last six months”.

During the same interview, Ms Sharpe explained how the current funding squeeze has left pharmacies with "a lot of debt" in "a really desperate position". Find out what else she discussed here.

What do you think PSNC's priorities should be in 2018?

Related Content

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD009131

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel